LRMR

Larimar Therapeutics Inc

NASDAQ: LRMR · HEALTHCARE · BIOTECHNOLOGY

$3.63

-5.22% today

Updated 2026-07-29

Market cap

$397.87M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.02

Dividend yield

—

52W range

$3 – $6

Volume

2.3M

Market cap

$397.87M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.02

Dividend yield

—

52W range

$3 – $6

Volume

2.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-6.6

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$14.40

+296.69%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.02x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -6.60 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-44.61M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-34.18M	$-36.95M	$-80.60M	$-165.67M	$-29.61M
EPS	—	—	—	—	$-2.02
Free cash flow	$-27.67M	$-33.62M	$-71.28M	$-113.29M	$-44.61M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-07-06	HAMILTON, THOMAS EDWARD	Buy	50,000	$3.34
2026-05-19	TRUITT, JOSEPH	Buy	55,150	—
2026-05-19	THOMAS, FRANK E	Buy	55,150	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
LRMR	$397.87M	28	4.3	3.0	5.0	6.0	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$615.36B	57	4.7	8.5	4.3	6.0	—	Buy
ABBV	$447.53B	63	4.0	8.0	4.7	5.0	-78.83%	Buy
UNH	$391.69B	62	7.3	5.5	4.0	6.0	-30.51%	Buy
MRK	$307.25B	50	3.3	8.0	2.7	5.0	-62.28%	Hold

Smart narrative

Larimar Therapeutics Inc trades at $3.63. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -6.60, it sits in the distress.

Frequently asked questions

What is Larimar Therapeutics Inc's stock price?

Larimar Therapeutics Inc (LRMR) trades at $3.63.

Is Larimar Therapeutics Inc overvalued?

Larimar Therapeutics Inc carries a Smart Value Score of 28/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Larimar Therapeutics Inc (LRMR)?

The 12-month analyst consensus target is $14.40, about 296.7% above the current $3.63. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Larimar Therapeutics Inc's Altman Z-Score is -6.60, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

larimartx.com

Quick metrics

P/S ratio—

ROE-105.04%

Beta0.84

50D MA$3.57

200D MA$3.92

Shares out0.10B

Float0.06B

Short ratio—

Avg volume2.3M

Performance

1 week-4.73%

1 month+19.69%

3 months-11.75%

YTD+0.52%

1 year—

3 years—

5 years—

Compare

LRMR vs LLY →LRMR vs JNJ →LRMR vs ABBV →Stock screener →